Gambogic acid down-regulates MDM2 oncogene and induces p21Waf1/CIP1 expression independent of p53

Cancer Letters

Volumn 284, Issue 1, 2009, Pages 102-112

  Rong, Jing Jing ^a   Hu, Rong ^a   Qi, Qi ^a   Gu, Hong Yan ^a   Zhao, Qing ^a   Wang, Jia ^a   Mu, Rong ^a   You, Qi Dong ^a   Guo, Qing Long ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Anti tumor; Gambogic acid; MDM2; p21Waf1 CIP1; p53

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLOPHOSPHAMIDE; GAMBOGIC ACID; PROTEIN MDM2; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG DOSE COMPARISON; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION REGULATION; TUMOR; UBIQUITINATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53; XANTHONES;

EID: 69049088724     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.04.011     Document Type: Article

References (45)

1. Fakharzadeh S.S., Trusko S.P., and George D.L. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. 10 (1991) 1565-1569
2. Momand J., Zambetti G.P., Olson D.C., George D., and Levine A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69 (1992) 1237-1245
3. Oliner J.D., Kinzler K.W., Meltzer P.S., George D.L., and Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358 (1992) 80-83
4. Haupt Y., Maya R., Kazaz A., and Oren M. Mdm2 promotes the rapid degradation of p53. Nature 387 (1997) 296-299
5. Kubbutat M.H., Jones S.N., and Vousden K.H. Regulation of p53 stability by Mdm2. Nature 387 (1997) 299-303
6. Wu X., Bayle J.H., Olson D., and Levine A.J. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7 (1993) 1126-1132
7. Honda R., and Yasuda H. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene 19 (2000) 1473-1476
8. Zhang Z., and Zhang R. p53-independent activities of MDM2 and their relevance to cancer therapy. Curr. Cancer Drug Target. 5 (2005) 9-20
9. Xiao Z.X., Chen J., Levine A.J., Modjtahedi N., Xing J., Sellers W.R., et al. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375 (1995) 694-698
10. Martin K., Trouche D., Hagemeier C., Sørensen T.S., La Thangue N.B., and Kouzarides T. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 375 (1995) 691-694
11. Thomas A., and White E. Suppression of the p300-dependent mdm2 negative-feedback loop induces the p53 apoptotic function. Genes Dev. 12 (1998) 1975-1985
12. Tompkins V.S., Hagen J., Frazier A.A., Lushnikova T., Fitzgerald M.P., di Tommaso A., et al. A novel nuclear interactor of ARF and MDM2 (NIAM) that maintains chromosomal stability. J. Biol. Chem. 282 (2007) 1322-1333
13. Juven-Gershon T., Shifman O., Unger T., Elkeles A., Haupt Y., and Oren M. The Mdm2 oncoprotein interacts with the cell fate regulator Numb. Mol. Cell Biol. 18 (1998) 3974-3982
14. Boyd M.T., Vlatkovic N., and Haines D.S. A novel cellular protein (MTBP) binds to MDM2 and induces a G1 arrest that is suppressed by MDM2. J. Biol. Chem. 275 (2000) 31883-31890
15. Lundgren K., Montes de Oca Luna R., McNeill Y.B., Emerick E.P., Spencer B., Barfield C.R., et al. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev. 11 (1997) 714-725
16. Wang H., Zeng X., Oliver P., Le L.P., Chen J., Chen L., et al. MDM2 oncogene as a target for cancer therapy: an antisense approach. Int. J. Oncol. 15 (1999) 653-660
17. Lai Z., Yang T., Kin Y.B., Sielecki T.M., Diamond M.A., Strack P., et al. Differentiation of hdm2-mediated p53 ubiquitination and hdm2 autoubiquitination activity by small molecular weight inhibitors. Proc. Natl. Acad. Sci. USA 99 (2002) 14734-14739
18. Midgley C.A., Desterro J.M., Saville M.K., Howard S., Sparks A., Hay R.T., et al. An N-terminal p14ARF peptide blocks mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene 19 (2000) 2312-2323
19. Zhao L., Guo Q.L., You Q.D., Wu Z.Q., and Gu H.Y. Gambogic acid induces apoptosis and regulates expressions of Bax and Bcl-2 protein in human gastric carcinoma MGC-803 cells. Biol. Pharm. Bull. 27 (2004) 998-1003
20. Wu Z.Q., Guo Q.L., You Q.D., Zhao L., and Gu H.Y. Gambogic acid inhibits proliferation of human lung carcinoma SPC-A1 cells in vivo and in vitro and represses telomerase activity and telomerase reverse transcriptase mRNA expression in the cells. Biol. Pharm. Bull. 27 (2004) 1769-1774
21. Pandey M.K., Sung B., Ahn K.S., Kunnumakkara A.B., Chaturvedi M.M., and Aggarwal B.B. Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-kappaB signaling pathway. Blood 110 (2007) 3517-3525
22. Yu J., Guo Q.L., You Q.D., Zhao L., Gu H.Y., Yang Y., et al. Gambogic acid-induced G2/M phase cell-cycle arrest via disturbing CDK7-mediated phosphorylation of CDC2/p34 in human gastric carcinoma BGC-823 cells. Carcinogenesis 28 (2007) 632-638
23. Zhao Q., Yang Y., Yu J., You Q.D., Zeng S., Gu H.Y., et al. Posttranscriptional regulation of the telomerase hTERT by gambogic acid in human gastric carcinoma 823 cells. Cancer Lett. 262 (2008) 223-231
24. Yi T., Yi Z., Cho S.G., Luo J., Pandey M.K., Aggarwal B.B., et al. Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. Cancer Res. 68 (2008) 1843-1850
25. Qi Q., Lu N., Wang X.T., Gu H.Y., Yang Y., Liu W., et al. Anti-invasive effect of gambogic acid in MDA-MB-231 human breast carcinoma cells. Biochem. Cell Biol. 86 (2008) 386-395
26. Kasibhatla S., Jessen K.A., Maliartchouk S., Wang J.Y., English N.M., Drewe J., et al. A role for transferrin receptor in triggering apoptosis when targeted with gambogic acid. Proc. Natl. Acad. Sci. USA 102 (2005) 12095-12100
27. Gu H.Y., Wang X.T., Rao S., Wang J., Zhao J., Ren F.L., et al. Gambogic acid mediates apoptosis as a p53 inducer through down-regulation of mdm2 in wild-type p53-expressing cancer cells. Mol. Cancer Ther. 7 (2008) 3298-3305
28. Q.D. You, Q.L. Guo, F. Feng, W.Y. Liu, Chinese Patent ZL01008049. 3, 2003.
29. Zhang H.Z., Kasibhatla S., Wang Y., Herich J., Guastella J., Tseng B., et al. Discovery, characterization and SAR of gambogic acid as a potent apoptosis inducer by a HTS assay. Bioorg. Med. Chem. 12 (2004) 309-317
30. Arva N.C., Gopen T.R., Talbott K.E., Campbell L.E., Chicas A., White D.E., et al. A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J. Biol. Chem. 280 (2005) 26776-26787
31. Hu Y., Yang Y., You Q.D., Liu W., Gu H.Y., Zhao L., et al. Oroxylin A induced apoptosis of human hepatocellular carcinoma cell line HepG2 was involved in its antitumor activity. Biochem. Biophys. Res. Commun. 351 (2006) 521-527
32. Brown C.Y., Mize G.J., Pineda M., George D.L., and Morris D.R. Role of two upstream open reading frames in the translational control of oncogene mdm2. Oncogene 18 (1999) 5631-5637
33. Juven T., Barak Y., Zauberman A., George D.L., and Oren M. Wild-type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene 8 (1993) 3411-3416
34. Zauberman A., Flusberg D., Barak Y., and Oren M. A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acid. Res. 23 (1995) 2584-2592
35. Ries S., Biederer C., Woods D., Shifman O., Shirasawa S., Sasazuki T., et al. Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell (2000) 321-330
36. Chang C.J., Freeman D.J., and Wu H. PTEN regulates Mdm2 expression through the P1 promoter. J. Biol. Chem. 279 (2004) 29841-29848
37. Saucedo L.J., Myers C.D., and Perry M.E. Multiple murine double minute gene 2 (MDM2) proteins are induced by ultraviolet light. J. Biol. Chem. 274 (1999) 8161-8168
38. Stommel J.M., and Wahl G.M. Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation. EMBO J. 23 (2004) 1547-1556
39. Roth J., Dobbelstein M., Freedman D.A., Shenk T., and Levine A.J. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J. 17 (1998) 554-564
40. Ashcroft M., Ludwig R.L., Woods D.B., Copeland T.D., Weber H.O., MacRae E.J., et al. Phosphorylation of HDM2 by Akt. Oncogene 21 (2002) 1955-1962
41. Jin Y., Lee H., Zeng S.X., Dai M.S., and Lu H. MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation. EMBO J. 22 (2003) 6365-6377
42. Zhang Z., Wang H., Li M., Agrawal S., Chen X., and Zhang R. MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. J. Biol. Chem. 279 (2004) 16000-16006
43. Wood A., and Shilatifard A. Transcriptional blackjack with p21. Genes Dev. 20 (2006) 643-647
44. Sheaff R.J., Singer J.D., Swanger J., Smitherman M., Roberts J.M., and Clurman B.E. Proteasomal turnover of p21Cip1 does not require p21Cip1 ubiquitination. Mol. Cell 5 (2000) 403-410
45. Yang Y., Yang L., You Q.D., Nie F.F., Gu H.Y., Zhao L., et al. Differential apoptotic induction of gambogic acid, a novel anticancer natural product, on hepatoma cells and normal hepatocytes. Cancer Lett. 256 (2007) 259-266